A comprehensive view of AbbVie Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Housing & Economy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

AbbVie submits supplemental new drug application to FDA for Atogepant Qulipt, a preventive treatment for chronic migraines in adults; migraines affect 39 million people in US, are highest cause of disability for those under 50 years of age

FDA approves AbbVie’s Skyrizi injectable to treat moderate to severe active Crohn's disease in adults; drug is first new treatment for moderate to severe active CD in six years

Allergan Aesthetics publishes global trends report on drivers shaping the aesthetics market in the coming five years; report aims to help practitioners, industry players identify key developments, is available on company's website

AbbVie applies for US, international approval of ABBV-951 foscarbidopa/foslevodopa to treat advanced Parkinson's disease; drug delivered subcutaneously via a pump

AbbVie awarded license option for Cugene’s CUG252 Treg-selective IL-2 mutein injectable to treat autoimmune, inflammatory diseases for US$48.5M; Cugene plans Phase 1b trial in patients with autoimmune, inflammatory diseases during option period

Ask us about our Housing & Economy market view

Trending Chart

Interactive chart with headline count